Dr. Ginna G. Laport, MD is a Internal Medicine Physician - Hematology practicing in Stanford, CA
She has not yet shared a personalized biography with Doctor.com.
University | Degree | Focus | Graduated |
---|---|---|---|
U of Tx Medical School At Houston, Houston Tx | Other Degree | 1990 | |
University of Texas Medical School, Houston | Other Degree | 1990 |
Institution | Focus | Year |
---|---|---|
Residency - University of Chicago Hospitals | 1993 | |
Residency - University Of Chicago Hosps, Internal Medicine | Not Specified | |
Internship - University of Chicago Hospitals | 1991 | |
Fellowship - Stanford University School of Medicine,Stanford, Ca, United States | 1994 |
Certification | Cert. Body | Year |
---|---|---|
Internal medicine | Internal Medicine | Not Specified |
Position | Organization | Time |
---|---|---|
Professor of Medicine (Blood and Marrow Transplantation) | the Stanford University Medical Center | Present |
Publication | Publisher | Title | Published |
---|---|---|---|
Other Publication | Jourl of clinical oncology | Autologous or reduced | 2014 |
Other Publication | BRITISH JOURL OF HAEMATOLOGY | Autologous haematopoietic cell transplantation for non | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Graft-Versus-Host Disease | 2013 |
Other Publication | Kate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport | Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid | 2013 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Alterte Donor Hematopoietic Cell Transplantation | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Follicular Lymphoma: Prognostic Factors, Conventiol Therapies | 2012 |
Other Publication | Hari, P., Pasquini, M. C., Logan, B. R., Stadtmauer, E. A., Krishn, A. | Immunoglobulin Free Light Chain (FLC) and Heavy Chain | 2011 |
Other Publication | JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION | Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning | 2011 |
Other Publication | HAEMATOLOGICA-THE HEMATOLOGY JOURL | Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment | 2011 |
Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
Other Publication | ik, S. G., Negrin, R., Laport, G., Miklos, D., Shizuru, J., Arai, S., | Long-term outcomes of high-dose therapy using busulfan, etoposide | |
Other Publication | NEW ENGLAND JOURL OF MEDICINE | Protective conditioning for acute graft-versus-host disease | 2005 |
Other Publication | LEUKEMIA RESEARCH | Multiple unrelated clol abnormalities | 2004 |
Other Publication | JOURL OF HEMATOTHERAPY & STEM CELL RESEARCH | Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft | 2000 |
Other Publication | SEMIRS IN ONCOLOGY | The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma | 1998 |
Other Publication | SEMIRS IN ONCOLOGY | Treatment of adult acute lymphoblastic leukemia | 1997 |
Other Publication | Biology of blood and marrow transplantation | Total lymphoid irradiation-antithymocyte globulin conditioning | 2014 |
Other Publication | Journal of clinical oncology | Autologous or reduced | 2014 |
Other Publication | BLOOD | Prospective cohort study comparing intravenous busulfan to total body irradiation | 2013 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Simplified Validated Prognostic Model for Progression | 2013 |
Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | Autologous haematopoietic cell transplantation for non | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma | 2013 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Graft-Versus-Host Disease | 2013 |
Other Publication | Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Lapo | Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid | 2013 |
Other Publication | Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnsto | TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN | 2013 |
Other Publication | Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., John | Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic | |
Other Publication | BLOOD | Conditioning regimens for allotransplants for diffuse large B-cell lymphoma | 2012 |
Other Publication | BONE MARROW TRANSPLANTATION | Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Alternate Donor Hematopoietic Cell Transplantation | 2012 |
Other Publication | BLOOD | Prophylactic rituximab after allogeneic transplantation decreases B | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Tandem Transplantation for Follicular Lymphoma: The Best of Both Worlds? | 2012 |
Other Publication | BONE MARROW TRANSPLANTATION | Tandem chemo-mobilization followed by high | 2012 |
Other Publication | BONE MARROW TRANSPLANTATION | Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative | 2012 |
Other Publication | Hematology / the Education Program of the American Society of Hematolo | Changing role of stem cell transplantation in follicular lymphoma. | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Follicular Lymphoma: Prognostic Factors, Conventional Therapies | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy | 2012 |
Other Publication | LANCET ONCOLOGY | Autologous haemopoietic stem | 2011 |
Other Publication | Hari, P., Pasquini, M. C., Logan, B. R., Stadtmauer, E. A., Krishnan, | Immunoglobulin Free Light Chain (FLC) and Heavy Chain | 2011 |
Other Publication | JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning | 2011 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Adoptive Immunotherapy with Cytokine | 2011 |
Other Publication | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment | 2011 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Autologous versus Reduced | 2011 |
Other Publication | Mueller, A. M., Kohrt, H. E., Laport, G. G., Negrin, R. S., Cha, S., W | LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS | 2011 |
Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
Other Publication | CURRENT OPINION IN ONCOLOGY | Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy | 2010 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Phase I/II Trial of GN-BVC | 2010 |
Other Publication | Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., N | Noninvasive Prediction of Graft-Versus | 2010 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation | 2010 |
Other Publication | BONE MARROW TRANSPLANTATION | Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged | 2010 |
Other Publication | BLOOD | TLI and ATG conditioning with low risk of graft-versus | 2009 |
Other Publication | Naik, S. G., Negrin, R., Laport, G., Miklos, D., Shizuru, J., Arai, S. | Long-term outcomes of high-dose therapy using busulfan, etoposide | |
Other Publication | Kohrt, H., Turnbull, B., Laport, G., Miklos, D., Shizuru, J., Johnston | Outcomes Following Allogeneic Hematopoietic Cell Transplantation | 2008 |
Other Publication | Arai, S., Sahaf, B., Jones, C., Zhender, J., Lowsky, R., Strober, S., | Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results | 2008 |
Other Publication | Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., Miklos, | Phase I/II Trial of a Novel Gemcitabine | 2008 |
Other Publication | BLOOD | Long-term remission of Philadelphia chromosome | 2008 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma | 2008 |
Other Publication | Laport, G., Bredeson, C., Tomblyn, M. R., Kahl, B. S., Goodman, S. A., | Autologous versus reduced | |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Reduced-intensity conditioning follow by allogeneic hematopoietic cell transplantation for adult | 2008 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Controversies in lymphoma | 2008 |
Other Publication | LEUKEMIA & LYMPHOMA | Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review | 2008 |
Other Publication | Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., Lowsky, R. | Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy | 2007 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Mantle cell lymphoma in first complete remission | 2007 |
Other Publication | Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., | Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin | 2007 |
Other Publication | Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., | Rituximab infusion two months after nonmyeloablative transplantation maintains B | 2006 |
Other Publication | Lowsky, R., Stockert-Goldstein, K., Laport, G., Miklos, D., Arai, S., | Clinical outcomes following allogeneic hematopoietic cell transplantation | 2006 |
Other Publication | Laport, G. G., Sheehan, K., Lowsky, R., Shizuru, J. A., Stockerl-Golds | Cytokine induced killer | 2006 |
Other Publication | Cao, T. M., Stockerl-Goldstein, K. E., Cao, P. D., Laport, G. G., Shee | High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse | 2006 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | High-dose carmustine, etoposide | 2006 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma | 2006 |
Other Publication | Lowsky, R., Heydari, K., Sahaf, B., Shizuru, J., Laport, G., Johnston, | Haploidentical non-myeloablative allogeneic hematopoietic cell transplantation | 2005 |
Other Publication | BONE MARROW TRANSPLANTATION | Rhabdomyolysis after concomitant use of cyclosporine | 2005 |
Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | Protective conditioning for acute graft-versus-host disease | 2005 |
Other Publication | Arai, S., Negrin, R., Blume, K., Johnston, L., Laport, G., Lowsky, R., | A phase I trial with extended cohort of gemcitabine | 2005 |
Other Publication | BLOOD | Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell | 2005 |
Other Publication | EXPERIMENTAL HEMATOLOGY | CD34, CD49 and CD8 cell doses do not influence engraftment | 2005 |
Other Publication | Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., S | Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell | 2004 |
Other Publication | LEUKEMIA RESEARCH | Multiple unrelated clonal abnormalities | 2004 |
Other Publication | Lowsky, R., Jones, S. D., Mitra, S., Shizuru, J. A., Laport, G. G., St | Non-myeloablative conditioning with total lymphoid irradiation (TLI) | 2003 |
Other Publication | BLOOD | Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed | 2003 |
Other Publication | Current hematology reports | Nonmyeloablative allogeneic stem cell transplantation for acute leukemia. | 2003 |
Other Publication | BONE MARROW TRANSPLANTATION | A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients | 2001 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation | 2001 |
Other Publication | JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft | 2000 |
Other Publication | BONE MARROW TRANSPLANTATION | A dose escalation study of total body irradiation followed by high-dose etoposide | 2000 |
Other Publication | CYTOTHERAPY | Transplantation with low-density autologous PBSC prepared with BDS60 for women with stage II | 2000 |
Other Publication | SEMINARS IN ONCOLOGY | The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma | 1998 |
Other Publication | BONE MARROW TRANSPLANTATION | High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer | 1998 |
Other Publication | SEMINARS IN ONCOLOGY | Treatment of adult acute lymphoblastic leukemia | 1997 |
Internal Medicine
Years In Practice: 28 (started in 1997)
Accepts New Patients: Yes
Dr. Ginna G. Laport, MD has not yet listed the medications that she commonly prescribes.